Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccine with IL-12 and Alum or GM-CSF in Resected Melanoma
NCT00031733Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Feb 2002
- Primary completion
- Dec 2004
- Modality
- Whole Cell Cancer Vaccines, Peptides, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of tyrosinase + gp100 + mart-1 in melanoma, sponsored by University of Southern California. Started Feb 2002; status: completed.
02
Drugs
tyrosinase + gp100 + mart-1
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00031733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031733.